People With Movement Disorders May Become Immune to Botox Therapy

News Picture: People With Movement Disorders May Become Immune to Botox Therapy

FRIDAY, Dec. 28, 2018 (HealthDay News) -- Some people who receive botulinum toxin injections for disorders that cause muscle tightness and contractions develop resistance to the treatment, researchers say.

The new study included nearly 600 patients with dystonia or spasticity who had been receiving botulinum toxin type A (commonly known as "Botox") for about three to five years.

The researchers found that about 15 percent of the patients developed an immune response that made the treatment less effective or ineffective.

"People may be able to lessen their chances of developing this response by making sure the dose of the drug in each injection is as low as possible, the time between injections is not shortened and booster injections are avoided," study author Dr. Philipp Albrecht said in a news release from the American Academy of Neurology.

Albrecht is a member of the medical faculty at Heinrich Heine University in Dusseldorf, Germany.

The study findings were published online recently in the journal Neurology.

According to the American Association of Neurological Surgeons (AANS), spasticity is a condition in which certain muscles are continuously contracted, which can interfere with normal movement and speech. Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement.

Dystonia is a complex neurological disorder characterized by involuntary muscle contractions. As many as 250,000 people in the United States have dystonia, making it the third most common movement disorder after essential tremor and Parkinson's disease, the AANS says.

-- Robert Preidt

MedicalNews
Copyright © 2018 HealthDay. All rights reserved.

CONTINUE SCROLLING FOR NEXT NEWS ARTICLE

SLIDESHOW

Brain Food Pictures: What to Eat to Boost Focus See Slideshow

Health Solutions From Our Sponsors

References
SOURCE: American Academy of Neurology, news release, Nov. 29, 2018